Skip to main content
. Author manuscript; available in PMC: 2023 Aug 1.
Published in final edited form as: Pharmacol Ther. 2022 Jan 10;236:108112. doi: 10.1016/j.pharmthera.2022.108112

Figure 3. Mechanism for the anti-fibrotic activity of SCGB3A2.

Figure 3.

SCGB3A2 anti-fibrotic signaling starts upon binding of SCGB3A2 to a SCGB3A2 receptor, which activates STAT1 phosphorylation, increases SMAD7, and suppresses SMAD2/3 phosphorylation, resulting in the suppression of expression of genes involved in fibrosis such as collagens, leading to inhibition of fibrosis.